Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis
Loss of a tumor-suppressing protein accelerates B-cell lymphoma and predicts poor outcomes, opening new therapeutic targets including Myc inhibition.
RFX7 functions as a novel B-cell tumor suppressor that normally limits Myc activity; its loss-of-function mutations, found across human B-cell malignancies, accelerate lymphomagenesis in mouse models and correlate with inferior DLBCL prognosis. The findings establish RFX7-Myc and RFX7-AID axes as tractable targets for intervention and provide a mechanistic rationale for Myc inhibition in RFX7-deficient lymphomas.
What the study was
- Study design
- Mechanistic mouse model study with human genomic correlation
- Population
- B cell lymphoma mouse models; human DLBCL genomic/expression datasets
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Nature Immunology
Why it surfaced
High-impact journal (Nature Immunology) reporting a novel tumor suppressor in B-cell malignancies with direct prognostic relevance in human DLBCL; Myc is a high-interest therapeutic target; finding is preclinical but mechanistically well-characterized.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.